Premedical Student Exposure to Pharmaceutical Marketing: Too Much, Too Soon?
Toby Keys, MA, MPH; Mark Ryan, MD; Sharon Dobie, MD; David Satin, MD; David Evans, MD BACKGROUND AND OBJECTIVES: Direct pharmaceutical marketing to physicians by pharmaceutical representatives is effective in changing behavior of health care providers, resulting in less evidence-based prescribing. Although much has been written about pharmaceutical marketing exposures among medical students, less is known about direct marketing exposures before students matriculate. This study examined the types of pharmaceutical representative direct marketing exposures for premedical students and where they occurred.
METHODS: From June to August of 2017, researchers surveyed students who accepted admission to US public medical schools. These prematriculated students completed our survey just prior to matriculation. The survey inquired about whether the students were exposed to pharmaceutical marketing directly from pharmaceutical salespeople, the types of marketing they observed or received, and where these interactions occurred.
RESULTS: Survey participants included 911 prematriculated students from 14 of the 188 medical schools invited to participate. Seventy-one percent (646) of the participants received or observed someone receiving pharmaceutical marketing gifts, small meals or snacks, articles, or samples. The two most common contexts for direct pharmaceutical marketing exposures were during shadowing experiences (54%, 346) and during employment (50%, 323).
CONCLUSIONS:
The findings suggest that it may be common for medical students to have interacted directly with pharmaceutical salespeople or observed other health professionals in these interactions before they matriculate in medical school. Because many of these interactions occur during clinical experiences required by institutions for admission, medical schools and premedical associations should consider delivering conflict-of-interest education early in medical school education or before students matriculate.
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are interacting with pharmaceutical representatives this decade compared to last. [12] [13] [14] [15] [16] [17] Similar trends are observed with training programs. 18, 19 Despite the positive changes, the impact of the pharmaceutical industry-physician relationship continues to be felt. A 2012 Pew Foundation report found that the pharmaceutical industry is spending eight times more on direct pharmaceutical marketing to clinicians compared to marketing to consumers through mass media. There are an estimated 72,000 pharmaceutical representatives in the United States alone. 20 Generalists, on average, receive two visits per day from pharmaceutical sales representatives. 21 Medical students, faculty, and national organizations have all called for professionalism education around the physician-pharmaceutical industry relationship. [22] [23] [24] [25] [26] As a result, in many schools medical students receive professionalism training that includes managing the physician-pharmaceutical industry relationship. However, if learners are exposed to direct pharmaceutical marketing before they even reach medical school, these efforts might be too late. Additionally, premedical student exposure to pharmaceutical marketing risks normalization of a conflict of interest known to lead to prescribing patterns that deviate from evidence-based practices. Students who feel that physician exposure to pharmaceutical marketing is acceptable or beneficial may sustain such exposure in their future training and practice despite its wellknown harms.
To our knowledge, there has been only one study that has examined the context and prevalence of direct pharmaceutical marketing exposure among premedical students. Hodges et al found widespread exposure to pharmaceutical marketing among its students prior to entry into medical school. Additionally, they found shadowing was a common occasion for premedical students to interact with or observe pharmaceutical sales representatives. That study, however, was limited to a single school and was at high risk of recall bias because it surveyed students after matriculation into medical school, and in some cases in their fourth year of medical school. 27 Our objective was to conduct a national study to further validate past findings of this localized study and further explore the prevalence and context of premedical students' exposure to marketing delivered directly from pharmaceutical salespeople.
Methods

Participants
From March to June of 2017, our research group contacted deans of admissions or admissions administrators at all public medical schools in the United States requesting permission to survey their students who accepted admission to the entering 2017 class who had not yet matriculated at their institution. Study details and invitations to admissions deans to participate were issued by email. Follow-up phone calls were made to institutions that did not initially respond.
Those medical schools that chose to participate sent a scripted email invitation that our research team developed to their prematriculated medical students, inviting them to complete an online survey. Most participating institutions sent out reminder emails to participate. Student participation was voluntary and anonymous. Participants were encouraged to contact our research team if they had questions about the study.
Survey
Survey questions were based on a literature review and our previous research experiences in this area of inquiry. [27] [28] [29] [30] [31] [32] [33] The survey queried the extent to which prematriculated medical students observed or received direct pharmaceutical marketing from a salesperson. Those who answered yes to any type of observed or received marketing interaction were asked a follow-up question about the context in which this interaction occurred (Table 1) . We piloted the survey with two current medical students at the University of Washington for clarity, ease of use, and user acceptability.
Data Collection and Analysis
Data was collected from June to August 2017. We used a secure online web-based survey to collect student responses (UW Catalyst). Descriptive statistics were computed. An error in the survey logic prevented capture of student responses to one of the survey questions, "observing someone receiving a gift." This question was excluded from our analysis.
The University of Washington Human Subjects Division reviewed this study and gave it exempt status.
Results
Among the 188 pubic medical schools invited, 14 chose to participate (7% response rate). Table 1 shows the survey questions asked to each participant. Nine hundred eleven of 2,285 (40%) prematriculated students at participating institutions responded to the survey ( Table 2 ). The mean age of the prematriculated participants was 25 years with a range of 21 to 44 years; 47% were female. Participating institutions were located in all four US census regions: three medical schools (302 participants) from the South; seven medical schools (342 participants) from the Midwest; one medical school (66 participants) from the Northeast; and two medical schools (200 participants) from the West. Figure 1 shows the percentage of participants who reported exposure to pharmaceutical marketing from a salesperson or observing others being similarly exposed to direct pharmaceutical marketing. Students observed others receiving a small meal or snack, articles, and samples more than they themselves received these items. The most common exposure was for students to personally receive (34%, 310) or to observe someone receiving (49%, 444) a small meal or snack.
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The majority of students (71%, 646) received or observed someone receiving at least one type of pharmaceutical marketing exposure (Figure 2 ). In addition, 40% (360) of the participants reported three or more different types of direct marketing exposures. Only 29% (265) reported no direct marketing exposures. The Northeast represented the highest percentage of pharmaceutical marketing exposure (82%, 54), followed by the South at 77% (232), the West at 70% (137) and the Midwest at 64% (220).
Among the prematriculated students who reported a pharmaceutical marketing interaction with a sales representative, a majority reported that their exposures took place while either shadowing (54%, 346) or during previous employment (50%, 323). Figure 3 illustrates the context in which premedical students encountered direct pharmaceutical marketing.
Discussion
This survey of premedical students matriculating into medical school examined the prevalence and context of prior direct pharmaceutical marketing interactions. Most participants in the study entered medical school already having been exposed to some type of direct marketing from pharmaceutical salespeople. We also found that shadowing experiences were the most common place where premedical students encountered direct pharmaceutical marketing.
If premedical students form a favorable impression of pharmaceutical companies based on marketing exposure delivered to themselves or their mentors prior to matriculation, they may sustain or welcome such exposures later in their training and be more vulnerable to non-evidencebased influence on their prescribing. [28] [29] [30] [31] [32] [33] Given that many students appear to be exposed to this type of pharmaceutical marketing before they arrive at medical school, the current interventions may be too late or insufficient to counteract earlier, more favorable premedical student impressions about pharmaceutical marketing.
With medical schools requiring applicants to gain experience in medicine and medical practice, most students seek volunteer, shadowing, or work experiences (such as working as a medical assistant or scribe) in a medical setting. The expectation on the part of medical schools for this medical experience places applicants at risk of being influenced by direct-to-physician pharmaceutical marketing before they can be advised of the risks and potential harms of such marketing. This raises the issue of whether medical schools and premedical organizations should be providing guidance or making educational materials available to premedical students in order to increase their awareness of the known downsides of physician/pharmaceutical company interactions.
This study has a number of strengths. It was a national study that included premedical participation from all four US census regions. The survey questions were based on our review of the literature and our research team's previous research experience in this area. [27] [28] [29] [30] [31] [32] [33] The study also has important limitations. Fourteen of 188 identified US public medical schools elected 20 received or observed someone receiving a drug sample, a journal article, snack or meal, or a small gift (i.e. pens, notepads, pen lights, gift cards etc.) from a pharmaceutical salesperson. Because an error in the survey, we did not collect information on respondents observing others receiving a gift. Participants were asked if they had ever directly received or observed someone receiving a drug sample, a journal article, snack or meal, or a small gift (eg, pens, notepads, pen lights, gift cards, etc) from a pharmaceutical salesperson. Because of an error in the survey, we did not collect information on respondents observing others receiving a gift. 
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to participate in this study (7% response rate). Further, among participating universities, we experienced a relatively low response rate (40%) from the prematriculating students.
The study design also excluded those premedical students who did not matriculate into a public medical school. Although nonparticipant students' experiences with pharmaceutical marketing may differ from the experiences of our participants in a nonrandom fashion, it is unclear whether this is actually the case, and whether it would increase or decrease the overall incidence of exposure in our sample. Another limitation is the possibility of recall bias. The survey asked respondents to report past exposures. Accordingly, there is likelihood that not all responses accurately detailed all pharmaceutical sales encounters. However, this study reports on accepted medical students before they enter medical school, potentially minimizing recall bias seen in previous studies. In addition, the small number of respondents from the Northeast region limits the generalizability of any conclusions that might be drawn in comparison to other regions. Finally, there was no comparison group, nor was there representation of matriculants from most public medical schools or any private medical schools. Nonetheless, for those responding institutions, premedical student exposure to direct pharmaceutical marketing was observed or received by the majority of respondents.
Recommendations
We recommend that medical schools consider ways to mitigate the potential unintended consequences of premedical shadowing requirements. One approach is to offer educational material on admissions websites that inform premedical students about conflicts of interest that can arise from direct pharmaceutical marketing exposure. In addition, medical schools should also consider providing conflict-of-interest training as early as orientation. Medical associations can also play a role by educating their members about this issue and discouraging pharmaceutical salespeople visits, particularly when learners are in their clinics. Finally, premedical organizations should also provide conflict-of-interest training to their members. 
